Literature DB >> 19271102

IVIG trials in MS. Is albumin a placebo?

Otto R Hommes, Judith Haas, Per Soelberg-Sorenson, Mieke Friedrichs.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19271102     DOI： 10.1007/s00415-009-0893-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  18 in total

1.  Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.

Authors:  P S Sorensen; F Fazekas; M Lee
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

2.  IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

Authors:  P Soelberg Sorensen; J Haas; F Sellebjerg; T Olsson; M Ravnborg
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

3.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.

Authors:  P S Sorensen; B Wanscher; C V Jensen; K Schreiber; M Blinkenberg; M Ravnborg; H Kirsmeier; V A Larsen; M L Lee
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.

Authors:  J H Noseworthy; P C O'Brien; T M Petterson; J Weis; L Stevens; W K Peterson; D Sneve; S A Cross; J A Leavitt; R G Auger; B G Weinshenker; D W Dodick; D M Wingerchuk; M Rodriguez
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

5.  Is intravenous albumin a placebo?

Authors:  E Rewald; N Saito; Y Kohgo; N Takemori
Journal:  Lancet       Date:  1995-12-02       Impact factor: 79.321

6.  The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

Authors:  B Koçer; S Yildirim-Gürel; E T Tali; C Irkeç; S Işik
Journal:  Neuroradiology       Date:  2004-03-04       Impact factor: 2.804

7.  Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

Authors:  Otto R Hommes; Per S Sørensen; Franz Fazekas; Monika Maas Enriquez; Hans W Koelmel; Oscar Fernandez; Carlo Pozzilli; Paul O'Connor
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.

Authors:  Anat Achiron; Irena Kishner; Ida Sarova-Pinhas; Havi Raz; Meir Faibel; Yael Stern; Mor Lavie; M Gurevich; Mark Dolev; David Magalashvili; Yoram Barak
Journal:  Arch Neurol       Date:  2004-10

9.  A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

Authors:  L H Visser; R Beekman; C C Tijssen; B M J Uitdehaag; M L Lee; K L L Movig; A W Lenderink
Journal:  Mult Scler       Date:  2004-02       Impact factor: 6.312

10.  Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.

Authors:  D Pöhlau; H Przuntek; M Sailer; F Bethke; J Koehler; N König; C Heesen; P Späth; I Andresen
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.